Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Multi-Day Momos -- Ignore unavailable to you. Want to Upgrade?

To: Lawrence Burg who wrote (5)	3/17/1999 3:27:00 AM
From: Lawrence Burg	Read Replies (4) \| Respond to of 397

BLSI, a development stage biotechnology company, is engaged in the research and development of novel therapeutic and diagnostic products to treat chronic debilitating diseases such as cancer, central nervous system disorders and autoimmune diseases. For the nine months ended 9/98, revenues totaled $0, down from $83 thousand. Net loss fell 16% to $5 million. Revenue reflect the end of the Zeneca agreement. Lower loss reflects the completion of the THERAFECTIN clinical trials. OS/F 13.3/11.7...TA corrected but within uptrending bands. The high volume today is not that good, but there are 2 nice pennants in Jan & Feb, with a 3rd started in March, which ran through early, to 10+. Expect it to base again around $7, but keep an eye on compromises to the underlying TA trends. Little IAction. The play: Check TA on Monday.